Skip to main content
Top
Published in: Malaria Journal 1/2010

Open Access 01-12-2010 | Research

Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria

Authors: Nguyen H Phu, Phung Q Tuan, Nicholas Day, Nguyen TH Mai, Tran TH Chau, Ly V Chuong, Dinh X Sinh, Nicholas J White, Jeremy Farrar, Tran T Hien

Published in: Malaria Journal | Issue 1/2010

Login to get access

Abstract

Background

Both artemether and artesunate have been shown to be superior to quinine for the treatment of severe falciparum malaria in Southeast Asian adults, although the magnitude of the superiority has been greater for artesunate than artemether. These two artemisinin derivatives had not been compared in a randomized trial.

Methods

A randomized double blind trial in 370 adults with severe falciparum malaria; 186 received intramuscular artesunate (2.4 mg/kg immediately followed by 1.2 mg/kg at 12 hours then 24 hours then daily) and 184 received intramuscular artemether (3.6 mg per kilogram immediately followed by 1.8 mg per kilogram daily) was conducted in Viet Nam. Both drugs were given for a minimum of 72 hours.

Results

There were 13 deaths in the artesunate group (7 percent) and 24 in the artemether group (13 percent); P = 0.052; relative risk of death in the patients given artesunate, 0.54; (95 percent confidence interval 0.28-1.02). Parasitaemia declined more rapidly in the artesunate group. Both drugs were very well tolerated.

Conclusions

Intramuscular artesunate may be superior to intramuscular artemether for the treatment of severe malaria in adults.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization: Guidelines for the treatment of malaria. 2006 World Health Organization: Guidelines for the treatment of malaria. 2006
2.
go back to reference Dondorp AM, Nosten F, Stepniewska K, Day NPJ, White NJ, for the The South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005, 366: 717-25. 10.1016/S0140-6736(05)67176-0.CrossRefPubMed Dondorp AM, Nosten F, Stepniewska K, Day NPJ, White NJ, for the The South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005, 366: 717-25. 10.1016/S0140-6736(05)67176-0.CrossRefPubMed
3.
go back to reference Artemether-Quinine Meta-analysis Study Group: A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg. 2001, 95: 637-650. 10.1016/S0035-9203(01)90104-X.CrossRef Artemether-Quinine Meta-analysis Study Group: A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg. 2001, 95: 637-650. 10.1016/S0035-9203(01)90104-X.CrossRef
4.
go back to reference Hien TT, Day NP, Nguyen HP, Nguyen TH, Tran TH, Pham PL, Dinh XS, Ly VC, Ha V, Waller D, Peto TE, White NJ: A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996, 335: 76-83. 10.1056/NEJM199607113350202.CrossRef Hien TT, Day NP, Nguyen HP, Nguyen TH, Tran TH, Pham PL, Dinh XS, Ly VC, Ha V, Waller D, Peto TE, White NJ: A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996, 335: 76-83. 10.1056/NEJM199607113350202.CrossRef
5.
go back to reference Murphy SA, Mberu E, Muhia D, English M, Crawley J, Waruiru C, Lowe B, Newton CR, Winstanley P, Marsh K, Watkins WM: The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans R Soc Trop Med Hyg. 1997, 91: 331-334. 10.1016/S0035-9203(97)90097-3.CrossRefPubMed Murphy SA, Mberu E, Muhia D, English M, Crawley J, Waruiru C, Lowe B, Newton CR, Winstanley P, Marsh K, Watkins WM: The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans R Soc Trop Med Hyg. 1997, 91: 331-334. 10.1016/S0035-9203(97)90097-3.CrossRefPubMed
6.
go back to reference Hien TT, Davis TM, Chuong LV, Ilett KF, Sinh DX, Phu NH, Agus C, Chiswell GM, White NJ, Farrar J: Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother. 2004, 48: 4234-4239. 10.1128/AAC.48.11.4234-4239.2004.PubMedCentralCrossRefPubMed Hien TT, Davis TM, Chuong LV, Ilett KF, Sinh DX, Phu NH, Agus C, Chiswell GM, White NJ, Farrar J: Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother. 2004, 48: 4234-4239. 10.1128/AAC.48.11.4234-4239.2004.PubMedCentralCrossRefPubMed
7.
go back to reference Nealon C, Dzeing A, Muller-Romer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, Krishna S: Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother. 2002, 46: 3933-3939. 10.1128/AAC.46.12.3933-3939.2002.PubMedCentralCrossRefPubMed Nealon C, Dzeing A, Muller-Romer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, Krishna S: Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother. 2002, 46: 3933-3939. 10.1128/AAC.46.12.3933-3939.2002.PubMedCentralCrossRefPubMed
8.
go back to reference Ilett KF, Batty KT, Powell SM, Binh TQ, Thu le TA, Phuong HL, Hung NC, Davis TM: The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol. 2002, 53: 23-30. 10.1046/j.0306-5251.2001.01519.x.PubMedCentralCrossRefPubMed Ilett KF, Batty KT, Powell SM, Binh TQ, Thu le TA, Phuong HL, Hung NC, Davis TM: The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol. 2002, 53: 23-30. 10.1046/j.0306-5251.2001.01519.x.PubMedCentralCrossRefPubMed
9.
go back to reference Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sooklo P, Wimonwaltrawatee T, Looareeswuan S, White NJ, Nosten F: Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Thailand during five years of extensive artesunate-mefloquine use. Trans R Soc Trop Med Hyg. 2000, 94: 537-544. 10.1016/S0035-9203(00)90080-4.PubMedCentralCrossRefPubMed Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sooklo P, Wimonwaltrawatee T, Looareeswuan S, White NJ, Nosten F: Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Thailand during five years of extensive artesunate-mefloquine use. Trans R Soc Trop Med Hyg. 2000, 94: 537-544. 10.1016/S0035-9203(00)90080-4.PubMedCentralCrossRefPubMed
Metadata
Title
Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria
Authors
Nguyen H Phu
Phung Q Tuan
Nicholas Day
Nguyen TH Mai
Tran TH Chau
Ly V Chuong
Dinh X Sinh
Nicholas J White
Jeremy Farrar
Tran T Hien
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2010
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-9-97

Other articles of this Issue 1/2010

Malaria Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.